Abstract
Involvement of kidney in systemic lupus erythematosus has known to give major impact on the course of disease. Despite the advancement of treatment of lupus nephritis (LN), significant proportion of patients who are unresponsive to standard treatment. Optimizing treatment of LN remains important to reduce the morbidity and mortality of patients especially the survival disadvantage associated with chronic kidney disease and the side effects of the treatments. This study is conducted to recognize the response in using multi-target therapy ( Mycophenolic acid (MPA) and tacrolimus combination) as a rescue treatment for proliferative lupus nephritis and identifying factors that may affect the outcome of treatment in this group of patients.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call